Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of June 2025, with a specific report date of June 16, 2025. The registrant is a foreign private issuer based in Ramat Gan, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a conduit for a press release and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document. The filing focuses exclusively on a corporate announcement regarding clinical study progress.
Guidance, Outlook, and Management Commentary
On June 16, 2025, the company issued a press release (Exhibit 99.1) announcing plans to present progress from its Phase IIa Pancreatic Cancer study. This presentation is scheduled to occur during partnering meetings at the 2025 BIO International Convention in Boston. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the context of this clinical update.
Investor Verification Checklist
- Verify the content of the press release dated June 16, 2025, attached as Exhibit 99.1.
- Confirm the schedule and outcomes of the Phase IIa Pancreatic Cancer study presentation at the 2025 BIO International Convention.
- Review the company's most recent Form 20-F for actual financial performance data, as this 6-K contains none.